Accepted for/Published in: JMIR mHealth and uHealth
Date Submitted: Jul 29, 2020
Open Peer Review Period: Jul 29, 2020 - Sep 23, 2020
Date Accepted: Oct 16, 2020
(closed for review but you can still tweet)
Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.
ReMindCare app for Early Psychosis: clinical outcomes of a real-world intervention.
ABSTRACT
Background:
e-Health interventions are widely used in clinical trials and increasingly care setting as well; however, their efficacy in real-world contexts remains unknown. ReMindCare is a smartphone application that has been systematically implemented in a First Episode of Psychosis Program (FEPP) for patients with Early Psychosis (EP) since 2018.
Objective:
The objective of this study is to assess the efficacy of ReMindCare after 19 months of use in the clinic and varying use by individual patients
Methods:
The integration of ReMindCare app into the FEPP started on October 2018. Patients with EP self-selected to the app (RC group) or treatment as usual (TAU). The outcome variables considered were: adherence to the intervention, number of relapses, hospital admissions, and visits to urgent care units. Data from 90 patients with EP was analyzed: 59 on the RC group and 31 on the TAU group. Mean age of the sample was 32.8 (SD=9.4), 72.5% (66/90) were males, 91.2% (83/90) were Caucasian and 81.3% (74/90) were single.
Results:
Significant differences between RC and TAU groups were found in number of relapses, hospitalizations, and visits to urgent care units, with each showing benefits for the app. Only 20.3% (12/59) of patients from the RC Group had a relapse while 58% (18/31) of TAU patients had one or more relapses (X2= 13.7, p=0.001). Moreover, RC patients had less visits to urgent care units (X2= 7.4, p=0.006) and less hospitalizations than TAU patients (X2= 4.6, p=0.032). Mean of days using the app was 352.2 (SD=191.2; min/max: 18-594) and mean of engagement was 84.5 (16.04).
Conclusions:
To our knowledge this is the first e-Health intervention that has preliminary proven its benefits on the real-world treatment of patients with EP.
Citation
Request queued. Please wait while the file is being generated. It may take some time.
Copyright
© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.